patiromer Clinical Trials (2026): 25 Studies for Hyperkalemia & Hypertension
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
25 patiromer clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 12 indications (including Hyperkalemia & Hypertension) and 3,345 total planned enrollment. 5 Phase 3 patiromer trials and 9 Phase 2, 10 Phase 4 are listed. 3 patiromer clinical trials are actively recruiting at 11 U.S. sites across 9 states. Most recent activity: NCT05766839 (Dec 2030).
Where to Participate: All patiromer Trial Sites in the U.S. (11 sites across 9 states)
Every actively recruiting patiromertrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CO | Children's Hospital Colorado | Aurora80045 | NCT05766839 | Map |
| FL | Miller School of Medicine, University of Miami | Miami33124 | NCT05766839 | Map |
| FL | Arnold Palmer Hospital for Children | Orlando32806 | NCT05766839 | Map |
| GA | Augusta University - Children's Hospital of Georgia | Augusta30912 | NCT05766839 | Map |
| IL | University of Illinois College of Medicine | Peoria61605 | NCT05766839 | Map |
| MA | Boston Children's Hospital | Boston02115 | NCT05766839 | Map |
| MO | Children's Mercy Hospitals and Clinics | Kansas City64108 | NCT05766839 | Map |
| NC | Duke University Hospital | Durham27710 | NCT05766839 | Map |
| NC | Duke University Hospital & Medical Center | Durham27710 | NCT05766839 | Map |
| PA | The Children's Hospital of Philadelphia | Philadelphia19104 | NCT05766839 | Map |
| TN | Vanderbilt Children's Hospital Neurology | Nashville37232 | NCT05766839 | Map |
patiromer clinical trials at a glance: phase × recruitment status
| Phase | recruiting | completed | terminated | Total |
|---|---|---|---|---|
| P2 | 1 | 6 | 2 | 9 |
| P3 | 1 | 4 | 5 | |
| P4 | 1 | 6 | 3 | 10 |
| N/A | 1 | 1 |
Recruiting patiromer clinical trials (3)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT05766839 | Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age | P2 | Hyperkalemia | 32 | Apr 2025 |
| NCT06256991 | PROMISEPotassium Correction for RAAS Optimization in Chronic Kidney Disease | P4 | Chronic Kidney Diseases | 44 | Apr 2024 |
| NCT06858280 | PRINCEPatiromer and Diet/hrQoL in Chronic Dialysis | P3 | Hyperkalaemia | 40 | Jul 2025 |
patiromer clinical trials by indication
Hyperkalemia (13)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05766839 | — | P2 | recruiting | Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age |
| NCT05136664 | Patiromer JADE | P3 | completed | Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects |
| NCT04443608 | PLATINUM | P4 | terminated | Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management |
| NCT03781089 | — | P4 | completed | Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients |
| NCT05029310 | TACPAT | P4 | completed | Effects of Patiromer on Pharmacokinetics of Immunosuppresive Drugs in Renal Transplant Recipients |
| NCT03888066 | DIAMOND | P3 | completed | Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND) |
| NCT03087058 | EMERALD | P2 | terminated | Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia |
| NCT03799926 | — | P2 | completed | Exploratory Study of ZG-801 for the Treatment of Hyperkalemia |
| + 5 more, see All trials below. | ||||
Chronic Kidney Diseases (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06256991 | PROMISE | P4 | recruiting | Potassium Correction for RAAS Optimization in Chronic Kidney Disease |
| NCT03183778 | — | P4 | completed | Use of Patiromer to Transition Chronic Kidney Disease Patients With Hyperkalemia to a Plant-rich Diet. |
Hyperkalaemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06858280 | PRINCE | P3 | recruiting | Patiromer and Diet/hrQoL in Chronic Dialysis |
Acute Hyperkalemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04585542 | KBindER | P4 | terminated | Comparison of Potassium Binders in the ER |
Heart Failure，Congestive (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04142788 | RELIEHF | P4 | terminated | RELieving Increasing oEdema Due to Heart Failure |
End Stage Renal Failure on Dialysis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03740048 | TWOPLUS-HD | P3 | completed | A Pilot Trial of Twice-weekly Versus Thrice-weekly Hemodialysis in Patients With Incident End-stage Kidney Disease |
ESRD (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03326583 | — | P2 | completed | The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia |
Acute Decompensated Heart Failure (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02823626 | — | N/A | completed | High-dose Aldosterone Antagonist for Acute Decompensated Heart Failure |
Kidney Failure, Chronic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02933450 | REDUCE | P4 | completed | Relypsa For ED Acute Hyperkalemia Control and Reduction (REDUCE) |
Chronic Kidney Disease (CKD) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01810939 | OPAL | P3 | completed | A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL) |
Chronic Kidney Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01371747 | AMETHYST-DN | P2 | completed | Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN) |
Heart Failure (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01130597 | — | P2 | completed | Evaluation of Patiromer Titration in Heart Failure Patients With Chronic Kidney Disease |
patiromer pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| PROMISE | NCT06256991 | P4 | recruiting | Chronic Kidney Diseases | 44 | — |
| KBindER | NCT04585542 | P4 | terminated | Acute Hyperkalemia | 37 | PMID 37016309 |
| PLATINUM | NCT04443608 | P4 | terminated | Hyperkalemia | 115 | PMID 41730555 |
| TACPAT | NCT05029310 | P4 | completed | Hyperkalemia | 13 | — |
| RELIEHF | NCT04142788 | P4 | terminated | Heart Failure，Congestive | 19 | — |
| REDUCE | NCT02933450 | P4 | completed | Kidney Failure, Chronic | 43 | — |
| TOURMALINE | NCT02694744 | P4 | completed | Hyperkalemia | 114 | PMID 32588430 |
| PRINCE | NCT06858280 | P3 | recruiting | Hyperkalaemia | 40 | — |
| Patiromer JADE | NCT05136664 | P3 | completed | Hyperkalemia | 262 | — |
| TWOPLUS-HD | NCT03740048 | P3 | completed | End Stage Renal Failure on Dialysis | 51 | PMID 33165001 |
| DIAMOND | NCT03888066 | P3 | completed | Hyperkalemia | 1,195 | PMID 39340493 |
| OPAL | NCT01810939 | P3 | completed | Chronic Kidney Disease (CKD) | 243 | — |
| EMERALD | NCT03087058 | P2 | terminated | Hyperkalemia | 23 | — |
| AMBER | NCT03071263 | P2 | completed | Hyperkalemia | 295 | PMID 31533906 |
| AMETHYST-DN | NCT01371747 | P2 | completed | Chronic Kidney Disease | 324 | PMID 29767459 |
| PEARL-HF | NCT00868439 | P2 | completed | Hyperkalemia | 120 | PMID 21208974 |
Terminated and withdrawn patiromer trials (5)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT04585542terminatedComparison of Potassium Binders in the ER
- NCT04443608terminatedPatiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management
- NCT04142788terminatedRELieving Increasing oEdema Due to Heart Failure
- NCT03087058terminatedPharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia
- NCT02033317terminatedAn Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis
All patiromer trials (25)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT05766839 | Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age | P2 | recruiting | 32 | Vifor Pharma, Inc. | Apr 2025 | |
| NCT06256991 | PROMISE | Potassium Correction for RAAS Optimization in Chronic Kidney Disease | P4 | recruiting | 44 | University Medical Center Groningen | Apr 2024 |
| NCT06858280 | PRINCE | Patiromer and Diet/hrQoL in Chronic Dialysis | P3 | recruiting | 40 | Mario Negri Institute for Pharmacological Research | Jul 2025 |
| NCT05136664 | Patiromer JADE | Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects | P3 | completed | 262 | Vifor Fresenius Medical Care Renal Pharma | Feb 2022 |
| NCT04585542 | KBindER | Comparison of Potassium Binders in the ER | P4 | terminated | 37 | University of California, Irvine | Oct 2020 |
| NCT04443608 | PLATINUM | Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management | P4 | terminated | 115 | Comprehensive Research Associates | Oct 2020 |
| NCT03781089 | Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients | P4 | completed | 36 | Duke University | Jun 2019 | |
| NCT05029310 | TACPAT | Effects of Patiromer on Pharmacokinetics of Immunosuppresive Drugs in Renal Transplant Recipients | P4 | completed | 13 | Oslo University Hospital | Sep 2021 |
| NCT04142788 | RELIEHF | RELieving Increasing oEdema Due to Heart Failure | P4 | terminated | 19 | NHS Greater Glasgow and Clyde | Aug 2020 |
| NCT03740048 | TWOPLUS-HD | A Pilot Trial of Twice-weekly Versus Thrice-weekly Hemodialysis in Patients With Incident End-stage Kidney Disease | P3 | completed | 51 | Wake Forest University Health Sciences | Jun 2019 |
| NCT03888066 | DIAMOND | Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND) | P3 | completed | 1,195 | Vifor Pharma, Inc. | Apr 2019 |
| NCT03087058 | EMERALD | Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia | P2 | terminated | 23 | Vifor Pharma, Inc. | Jul 2017 |
| NCT03799926 | Exploratory Study of ZG-801 for the Treatment of Hyperkalemia | P2 | completed | 184 | Zeria Pharmaceutical | Feb 2019 | |
| NCT03326583 | The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia | P2 | completed | 27 | Dominic Raj | Nov 2017 | |
| NCT03229265 | Pharmacokinetic Study of Tacrolimus and Mycophenolate Mofetil in Kidney Transplant Recipients With Hyperkalemia Receiving Patiromer | P4 | completed | 8 | The Rogosin Institute | Aug 2017 | |
| NCT03183778 | Use of Patiromer to Transition Chronic Kidney Disease Patients With Hyperkalemia to a Plant-rich Diet. | P4 | completed | 3 | NYU Langone Health | Mar 2018 | |
| NCT03071263 | AMBER | Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease | P2 | completed | 295 | Relypsa, Inc. | Jan 2017 |
| NCT02823626 | High-dose Aldosterone Antagonist for Acute Decompensated Heart Failure | — | completed | 48 | The University of Texas Health Science Center at San Antonio | Sep 2016 | |
| NCT02933450 | REDUCE | Relypsa For ED Acute Hyperkalemia Control and Reduction (REDUCE) | P4 | completed | 43 | Baylor College of Medicine | Aug 2016 |
| NCT02694744 | TOURMALINE | Patiromer With or Without Food for the Treatment of Hyperkalemia | P4 | completed | 114 | Relypsa, Inc. | Feb 2016 |
| NCT01810939 | OPAL | A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL) | P3 | completed | 243 | Relypsa, Inc. | Feb 2013 |
| NCT01371747 | AMETHYST-DN | Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN) | P2 | completed | 324 | Relypsa, Inc. | Jun 2011 |
| NCT01130597 | Evaluation of Patiromer Titration in Heart Failure Patients With Chronic Kidney Disease | P2 | completed | 63 | Relypsa, Inc. | May 2010 | |
| NCT00868439 | PEARL-HF | Evaluation of Patiromer in Heart Failure Patients | P2 | completed | 120 | Relypsa, Inc. | Apr 2009 |
| NCT02033317 | An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis | P2 | terminated | 6 | Relypsa, Inc. | Aug 2008 |
patiromer clinical trials: frequently asked questions
- How many patiromer clinical trials are there?
- 25 patiromer clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 3 are actively recruiting participants. 17 are marked completed.
- Are patiromer clinical trials recruiting in 2026?
- Yes — 3 patiromer trials are actively recruiting in 2026, with 11 U.S. sites across 9 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is patiromer being studied for?
- patiromer is being studied for Hyperkalemia, Hypertension, Chronic Kidney Diseases, Kidney Transplant, End Stage Renal Disease and 16 more. The trials are grouped by indication on this page.
- What phase is patiromer in?
- patiromer clinical trials span 10 Phase 4, 5 Phase 3, 9 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors patiromer clinical trials?
- The lead sponsor across the most patiromer trials is Relypsa, Inc., with 16 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming patiromeras an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: